Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 9/20 | 0.54 |
| ▸ | EDNRA | P25101 | 9/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.54 |
| ▸ | PKM | P14618 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.48 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12293031 | 0.84 | EDNRB (0.54) | EDNRBEDNRAHSD17B10PKMHPGD | |
| SCHEMBL471080 | 0.84 | MAPT (0.57) | EDNRBEDNRAHSD17B10PKMHPGD | |
| SCHEMBL7252032 | 0.74 | EDNRA (0.68) | EDNRBEDNRAABCC3ABCC4ABCB11 | |
| SCHEMBL6314152 | 0.74 | EDNRA (0.66) | EDNRBEDNRAHSD17B10ABCC3ABCC4 | |
| SCHEMBL27496629 | 0.72 | EDNRB (0.60) | EDNRBEDNRAHSD17B10PKMHPGD | |
| SCHEMBL7258840 | 0.71 | MAPT (0.66) | HSD17B10PKMHPGDMAPTMEN1 | |
| SCHEMBL7946892 | 0.71 | EDNRA (0.49) | EDNRBEDNRAHSD17B10ABCC3ABCC4 | |
| SCHEMBL4632032 | 0.70 | EDNRA (1.00) | EDNRBEDNRAABCC3ABCC4ABCB11 | |
| SCHEMBL6151248 | 0.70 | EDNRA (0.81) | EDNRBEDNRAABCC3ABCC4ABCB11 | |
| SCHEMBL6313203 | 0.70 | EDNRA (0.63) | EDNRBEDNRAHSD17B10ABCC3ABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895608-B2 | Sulfonamide anti-viral compounds | Kineta, Inc. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20130039945-A1 | Anti-Viral Compounds | Kineta, Inc. (US) | 2013-02-14 | — | — | US | disclosed |
| US-20130039887-A1 | Methods of Identifying and Using Anti-Viral Compounds | Kineta, Inc. (US) | 2013-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130039887-A1 | Methods of Identifying and Using Anti-Viral Compounds | MAVS, EIF2AK2, DDX5 | EDNRB 3389/4885EDNRA 3727/4885HSD17B10 4086/4885 |
| US-20130039945-A1 | Anti-Viral Compounds | MAVS, EIF2AK2, IRF3 | EDNRB 3587/4885EDNRA 3666/4885HSD17B10 4165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.